Validation of the histotype of commonly used ovarian carcinoma cell lines using immunohistochemistry based prediction via COSP and mutational profiling.

COSP and AIRD1A markers were scored as positive (1) or negative (0), except for p53: null mutation (0), wildtype (1), mutated (2).
ARID1A IHC: a – corresponding ARID1A nonsense or frameshift mutation detected, b – no ARID1A mutation detected in sequencing data (if no letter code, sequence information was unavailable)
COSP algorithm can be found at http://www.gpec.ubc.ca/index.php?content=papers/ovcasubtype.php
TP53 mutations are noted as heterozygous (het) or Homozygous/Hemizygous (Hm)
*Sequencing of BRAF, KRAS, ERBB2, NRAS, CTNNB1, EGFR, PTEN, PIK3CA, PPP2R1A, DICER1 and ARID1A

COSP标志物与ARID1A（AT富集相互作用结构域蛋白1A）的评分规则为阳性（1）或阴性（0），p53指标除外：p53无效突变（null mutation）记为0，野生型记为1，突变型记为2。
ARID1A免疫组织化学染色（Immunohistochemistry, IHC）标注规则：a——检测到对应ARID1A无义突变或移码突变；b——测序数据中未检测到ARID1A突变（若无字母代码，则表示序列信息不可得）。
COSP算法的详细信息可通过以下网址获取：http://www.gpec.ubc.ca/index.php?content=papers/ovcasubtype.php
TP53突变可标注为杂合突变（heterozygous, het）或纯合/半合子突变（homozygous/hemizygous, Hm）。
* 针对BRAF、KRAS、ERBB2、NRAS、CTNNB1、EGFR、PTEN、PIK3CA、PPP2R1A、DICER1及ARID1A开展测序。